Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glabellar Lines Clear all
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT01391312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin Type A, normal saline (placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

NCT03721016
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
QM1114-DP, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Homewood, Alabama • Manhattan Beach, California • Vista, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

NCT05148000
View directory record Official record
Conditions
Glabellar Frown Lines, Canthal Lines
Interventions
QM1114-DP
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jun 11, 2026, 7:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07427797
View directory record Official record
Conditions
Moderate to Severe Glabellar Lines
Interventions
IPN10200, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines

NCT01447342
View directory record Official record
Conditions
Facial Wrinkles, Skin Aging
Interventions
Cryo-Touch II
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Beverly Hills, California • Redwood City, California • Roseville, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01189760
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jun 11, 2026, 7:21 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

NCT05083286
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Encino, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 2 Interventional

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

NCT06246552
View directory record Official record
Conditions
Glabellar Lines
Interventions
JTM201, Placebo
Biological
Lead sponsor
Jetema USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 11, 2026, 7:21 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

NCT04715048
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
PrabotulinumtoxinA, Onabotulinum toxin A
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Jun 11, 2026, 7:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07435428
View directory record Official record
Conditions
Moderate to Severe Glabellar Lines
Interventions
IPN10200, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
41
States / cities
Los Angeles, California • Newport Beach, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

NCT06834789
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, OnabotulinumtoxinA, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Scottsdale, Arizona • Newport Beach, California • Redondo Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

NCT03786770
View directory record Official record
Conditions
Frown Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boca Raton, Florida • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jun 11, 2026, 7:21 AM EDT
Completed No phase listed Observational Results available

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

NCT01608672
View directory record Official record
Conditions
Glabellar Lines
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jun 11, 2026, 7:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

NCT01808742
View directory record Official record
Conditions
Frown Lines, Glabellar Frown Lines
Interventions
Treatment with CryoTouch III Device
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

NCT05129319
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
prabotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

NCT05248880
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Newport Beach, California • Redondo Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 11, 2026, 7:21 AM EDT
Terminated No phase listed Observational

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607
View directory record Official record
Conditions
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Glabellar Lines

NCT03795922
View directory record Official record
Conditions
Glabellar Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 11, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Results available

The Treatment of Glabellar Frown Lines

NCT02096081
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA, OnabotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jun 11, 2026, 7:21 AM EDT